Zhao 2021.

Study characteristics
Methods	Unblinded RCT
Participants	Outpatients with confirmed recurrent COVID‐19 (mild), isolated and treated at 5 centres in China
Interventions	Favipiravir, standard of care
Outcomes	Time to achieve two consecutive (at intervals of more than 24 hours) negative RT‐PCR result for SARS‐CoV‐2 RNA in nasopharyngeal swab and sputum sample; changes in routine blood test and CRP (C‐reactive protein); count and proportion of T lymphocyte subsets in peripheral blood and changes in cytokines; relationship between the antibody titre and the SARS‐CoV‐2 RNA re‐negative time; adverse events.
Notes

COVID‐19: coronavirus disease 2019; CT: computed tomography; ICU: intensive care unit; NEWS(2): National Early Warning Score (2); PaO₂/FiO₂: arterial oxygen partial pressure/fractional inspired oxygen; PCR: polymerase chain reaction; RCT: randomized controlled trial; RT‐PCR: reverse transcriptase polymerase chain reaction; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; SOC: standard of care; SpO₂: blood oxygen saturation